Says one lobbyist, “The administration is imposing foreign price controls from countries with socialized health care systems that deny their citizens access and discourage innovation.”
The lobbying groups for U.S. drugmakers aren't happy about President Donald Trump's plan to borrow from Europe's system of paying for some high-cost drugs.
On Thursday, Trump proposed cutting what Medicare pays for many costly drugs that are administered in hospitals and clinics, using a new index of prices that would bring U.S. government payments closer to what European countries pay.
“The administration is imposing foreign price controls from countries with socialized health care systems that deny their citizens access and discourage innovation,” said Steve Ubl, chief executive officer of the Pharmaceutical Research and Manufacturers of America, which represents drugmakers. The Biotechnology Innovation Organization, or BIO, said the administration would be “adopting foreign price controls.”
The drug industry is one of Washington's most powerful lobbying forces, spending tens of millions of dollars a year on lobbying and political contributions. Alex Azar, Trump's Secretary of Health and Human Services, attended an event hosted by BIO after the presentation, saying that the plan would not hurt research and development by the industry.
“You're going to find no more pro innovation secretary than me,” said Azar. “Yet today our actions have been accused of being so anti innovation as to be un-American by this very group.”
Trump and members of his administration have levied charges of socialized medicine at Democrats, saying a push for a “Medicare-for-all” health system would socialize American medicine.
At an event in Washington where Trump presented the proposed pricing changes, he also attacked Democrats, saying that “sadly a majority of Democrats in the House of Representatives have sponsored a very socialist program that would terminate Medicare.”
Read more:
- Pharma balks at proposal to list drug prices in TV ads
- Reference-based pricing: a panacea for high drug prices?
- Drug price transparency takes a step forward
Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
